Introduction:
The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately 30% of patients with acute myeloid leukemia (AML), with the majority being internal tandem duplication (ITD) mutations, 1 an alteration associated with higher relapse rates, and worse outcomes. [2] [3] [4] The FLT3-ITD protein product is a ligand-independent, constitutively active receptor tyrosine kinase, causing activation of multiple signaling cascades, suppression of apoptosis, and proliferation of myeloblasts. 5, 6 Several inhibitors of the FLT3-ITD protein are under clinical investigation.
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FLT3 inhibition causes direct cytotoxicity to myeloblasts. 11, 12 However, intriguingly, terminal differentiation of FLT3-ITD myeloblasts was recently reported in patients treated with quizartinib, a potent FLT3 inhibitor. 13 We now report the incidence of neutrophilic dermatoses in three FLT3-ITD patients treated with FLT3 inhibitors, and demonstrate that these infiltrating neutrophils retain FLT3-ITD expression, confirming the process of terminal differentiation induced by this therapy.
Methods:
Skin biopsy samples from three patients seen at the Massachusetts General Hospital and EGFR and MET gene copy number was evaluated by fluorescence in situ hybridization (FISH) on formalin-fixed paraffin-embedded tissue sections, as described previously.
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Results and Discussion:
Case histories are summarized below, and in 
Discussion:
Potent FLT3 inhibition appears to cause terminal differentiation of arrested myeloid precursors in AML. 13 The impact of FLT3-ITD mutation on differentiation is previously described, and release of differentiation block appears to be a feature of FLT3 inhibition. 16, 17 Differentiation and cell cycling are coordinated phenomena, and the transcription factor C/EBPα has been identified as an important mediator. 17 Dysfunction of C/EBPα activity is well-described in AML, and FLT3-ITD mutations inhibit C/EBPα. [17] [18] [19] FLT3 inhibition leads to cytotoxicity within days, with clearance of peripheral blasts, 13,20,21 but its impact on terminal differentiation usually follows over a period of weeks. 13 A similar timeframe was noted in our patients, with characteristic skin findings occurring weeks after therapy initiation.
We here describe a dermatologic manifestation of a "differentiation syndrome" that appears to follow initiation of FLT3 inhibition. These patients all developed painful subcutaneous nodules within weeks of starting therapy, with pathological evaluation revealing deep neutrophilic infiltration and panniculitis. Skin biopsy samples contained no myeloblasts but did express FLT3-ITD, as well as other cytogenetic or molecular aberrations that had characterized the patients' leukemic clone, suggesting that the infiltrating neutrophils were terminally differentiated from FLT3-mutant precursors. In For personal use only. on October 24, 2017. by guest www.bloodjournal.org From addition, in our patients, the extent of FLT3-mutant allelic burden did not appear to correspond to the development of neutrophilic dermatosis, although it is difficult to draw conclusions from this limited number of cases.
This syndrome appears to share features with the well-described phenomena associated with use of all-trans retinoic acid in acute promyelocytic leukemia, characterized by neutrophilic differentiation, with possible pulmonary and skin manifestations. 24 ATRAdifferentiated cells are known to over-express CXCR4, which interacts with the stromal factor, SDF-1, residing in affected tissues. 25 CXCR-4 expression is elevated in FLT3-ITD AML, 26, 27 potentially priming these cells upon differentiation for CXCR-4-mediated migration and SDF-1 interaction in tissues.
In light of these and similar findings, 13 we suggest that remissions resulting from FLT3 inhibition, as recently reported, 7,21 may differ in quality from those achieved following conventional chemotherapy. The latter are "kinetic" remissions due to repopulation, by normal precursors, of a cytoreduced marrow milieu, whereas remissions resulting from FLT3-inhibitors may be driven by terminal differentiation and gradual replacement of 
